<DOC>
	<DOCNO>NCT00586547</DOCNO>
	<brief_summary>This study design determine number donor lymphocytes give recipient haploidentical stem cell transplant depletion recipient-reactive T lymphocytes ex-vivo treatment fix dose RFT5-dgA immunotoxin , result rate Grade III/IV GVHD &lt; / = 25 % , analyze immune reconstitution patient , measure overall disease free survival , 100 day 1 year .</brief_summary>
	<brief_title>Evaluating Use RFT5-dgA Deplete Alloreactive Cells Prior Haploidentical Stem Cell Transplantation</brief_title>
	<detailed_description>Patients receive cytosine arabinoside ( 3g/m^2 ) IV every 12 hour 6 dos start 1400 hour day -8 . Cyclophosphamide ( 45mg/kg ) give Day -7 Day -6 . MESNA ( 45mg/kg , divide 5 dos ) administer 15 minute prior dose cyclophosphamide 3 , 6 , 9 and12 hour dose cyclophosphamide . Campath 1H IV give Days -3 , -2 -1 . TBI , total dose 14.0 Gy deliver 8 fraction 1.75 Gy two fraction per day begin Day -4 . The dose rate 10cGy/min . Approximately thirty day follow transplantation ( day +30 ) , cryopreserved T cell thaw infused catheter line normal saline . This study begin dose T cell know cause GvHD even haploidentical recipient , even T cell administer first allodepleted . A subset patient achieve engraftment include dose escalation study allodepleted T-cells treat RFT5-dgA . A continual reassessment method base logistic dose-response curve cohort size 2 employ determine MTD . Cohorts size 2 accrue begin dose level 1 dose-response curve estimate toxicity outcome observe determine recommend dose level next patient cohort . Each every patient receive five additional injection T cell dose , monthly interval , provide evidence grade 2 high GVHD , total T cell number &gt; 1000/ul Patients enter start level 1 , accord follow dos : Dose level -1 ( 1 x 10^3 T cells/Kg ) ; Dose level 1 ( 1 x 10^4 T cells/Kg ) ; Dose level 2 ( 1 x 10^5 T cells/Kg ) ; Dose level 3 ( 1 x 10^6 T cells/Kg ) ; Dose level 4 ( 5 x 10^6 T cells/Kg ) .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>ALL high grade NHL Stage III IV relapse consider primary refractory disease . Myelodysplastic syndrome . AML first relapse primary refractory disease . CML hemophagocytic lymphohistiocytosis ( HLH ) Familial hemophagocytic lymphohistiocytosis ( FLH ) Viralassociated hemophagocytic syndrome ( VAHS ) Xlinked lymphoproliferative disease ( XLP ) Patients Severe chronic active Epstein Barr virus infection ( SCAEBV ) predilection T NKcell malignancy Lack suitable conventional donor ( i.e . 5/6 6/6 related 5/6 6/6 unrelated donor ) presence rapidly progressive disease permit time identify unrelated donor . Donor cell collect frozen conditioning start . Patients life expectancy ( &lt; = 6 week ) limit disease leukemia . Patients symptomatic cardiac disease , evidence significant cardiac disease echocardiogram ( i.e . shorten fraction &lt; 25 % ) Patients severe renal disease ( i.e . creatinine clearance le 40cc/1.73m2 ) Patients preexist severe restrictive pulmonary disease ( FVC less 40 % predict ) Patients severe hepatic disease ( direct bilirubin great 3ug/dl SGPT great 500ug/dl ) Patients severe personality disorder mental illness would preclude compliance study Patients severe infection evaluation Principal Investigator preclude ablative chemotherapy successful transplantation Patients document HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Haploidentical</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Graft-Versus-Host disease</keyword>
</DOC>